BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pang Y, Kartsonaki C, Turnbull I, Guo Y, Clarke R, Chen Y, Bragg F, Yang L, Bian Z, Millwood IY, Hao J, Han X, Zang Y, Chen J, Li L, Holmes MV, Chen Z. Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People. Hepatology. 2018;68:1308-1318. [PMID: 29734463 DOI: 10.1002/hep.30083] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
Number Citing Articles
1 Garg K, Brackett S, Hirsch IB, Garg SK. NAFLD/NASH and Diabetes. Diabetes Technol Ther 2020;22:S174-86. [PMID: 32069155 DOI: 10.1089/dia.2020.2513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
3 Bai Z, Li B, Lin S, Liu B, Li Y, Zhu Q, Wu Y, Yang Y, Tang S, Meng F, Chen Y, Yuan S, Shao L, Qi X. Development and Validation of CAGIB Score for Evaluating the Prognosis of Cirrhosis with Acute Gastrointestinal Bleeding: A Retrospective Multicenter Study. Adv Ther 2019;36:3211-20. [PMID: 31512140 DOI: 10.1007/s12325-019-01083-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Zhang X, Wong VW, Yip TC, Tse YK, Liang LY, Hui VW, Li GL, Chan HL, Wong GL. Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study. Hepatol Commun 2021;5:1212-23. [PMID: 34278170 DOI: 10.1002/hep4.1705] [Reference Citation Analysis]
5 Pang Y, Kartsonaki C, Lv J, Millwood IY, Yu C, Guo Y, Chen Y, Bian Z, Yang L, Chen J, Clarke R, Walters R, Wu S, Li H, Holmes MV, Li L, Chen Z. Observational and Genetic Associations of Body Mass Index and Hepatobiliary Diseases in a Relatively Lean Chinese Population. JAMA Netw Open 2020;3:e2018721. [PMID: 33006619 DOI: 10.1001/jamanetworkopen.2020.18721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Seto WK. Chronic hepatitis B and metabolic risk factors: A call for rigorous longitudinal studies. World J Gastroenterol 2019; 25(3): 282-286 [PMID: 30686897 DOI: 10.3748/wjg.v25.i3.282] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17:e1003100. [PMID: 32353039 DOI: 10.1371/journal.pmed.1003100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
8 Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Curr Vasc Pharmacol 2020;18:172-81. [PMID: 30961499 DOI: 10.2174/1570161117666190405164313] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
9 Zhuo JY, Lu D, Lin ZY, Cen BN, Wei XY, Xie HY, Zheng SS, Xu X. CC motif chemokine ligand 16 inhibits the progression of liver cirrhosis via inactivating hepatic stellate cells. Hepatobiliary Pancreat Dis Int 2020;19:440-8. [PMID: 31948840 DOI: 10.1016/j.hbpd.2019.12.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Lonardo A, Lugari S, Ballestri S, Nascimbeni F, Baldelli E, Maurantonio M. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? Acta Diabetol 2019;56:385-96. [DOI: 10.1007/s00592-018-1266-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
11 Yu C, Song C, Lv J, Zhu M, Yu C, Guo Y, Yang L, Chen Y, Chen Z, Jiang T, Ma H, Jin G, Shen H, Hu Z, Li L; China Kadoorie Biobank Collaborative Group. Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people. Int J Cancer 2021;148:2924-34. [PMID: 33521941 DOI: 10.1002/ijc.33487] [Reference Citation Analysis]
12 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Chen Y, Yang L, Millwood IY, Walters RG, Wang S, Chen J, Chen Z, Li L. Metabolic risk factors, genetic predisposition, and risk of severe liver disease in Chinese: a prospective study of 0.5 million people. Am J Clin Nutr 2021;114:496-504. [PMID: 33964851 DOI: 10.1093/ajcn/nqab099] [Reference Citation Analysis]
13 Mao D, Lau ESH, Wu H, Yang A, Fan B, Shi M, Tam CHT, Chow E, Kong APS, Ma RCW, Luk A, Chan JCN. Risk Associations of Glycemic Burden and Obesity With Liver Cancer-A 10-Year Analysis of 15,280 Patients With Type 2 Diabetes. Hepatol Commun 2022. [PMID: 35044101 DOI: 10.1002/hep4.1891] [Reference Citation Analysis]
14 Zou Y, Yu M, Sheng G. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study. Lipids Health Dis 2020;19:145. [PMID: 32563249 DOI: 10.1186/s12944-020-01326-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Doycheva I, Zhang T, Amjad W, Thuluvath PJ. Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. J Clin Exp Hepatol 2020;10:296-303. [PMID: 32655232 DOI: 10.1016/j.jceh.2019.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Med Chem 2019;11:2171-92. [PMID: 31538528 DOI: 10.4155/fmc-2019-0003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
17 Chen J, Ding X, Wu R, Tong B, Zhao L, Lv H, Meng X, Liu Y, Ren B, Li J, Jian T, Li W. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition. J Agric Food Chem 2021;69:14176-91. [PMID: 34783554 DOI: 10.1021/acs.jafc.1c05596] [Reference Citation Analysis]
18 Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, Zhao J. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol 2019;54:1096-105. [PMID: 31134334 DOI: 10.1007/s00535-019-01594-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhang Y, Shi R, Yu L, Ji L, Li M, Hu F. Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes. Diabetes Ther 2020;11:2057-73. [PMID: 32725485 DOI: 10.1007/s13300-020-00893-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Fu R, Yu F, Wu W, Liu J, Li J, Guo F, Xu L, Wang F, Cui X. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding. Int Immunopharmacol 2021;101:108195. [PMID: 34678691 DOI: 10.1016/j.intimp.2021.108195] [Reference Citation Analysis]
21 Uzzaman A, Zhang X, Qiao Z, Zhan H, Sohail A, Wahid A, Shang Z, Guan X, Cao CX, Xiao H. Discovery of small extracellular vesicle proteins from human serum for liver cirrhosis and liver cancer. Biochimie 2020;177:132-41. [PMID: 32835735 DOI: 10.1016/j.biochi.2020.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Grecian SM, McLachlan S, Fallowfield JA, Hayes PC, Guha IN, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF, Strachan MWJ. Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Obes Sci Pract 2021;7:497-508. [PMID: 34631129 DOI: 10.1002/osp4.484] [Reference Citation Analysis]
23 Liu J, Zhi Q, Liu Y, Wang Y, Chen L, Ke Y, Zeng L, Wu X, Yang X, Guleng B, Liu H, Ren J. Insulin promotes hepatocarcinoma tumorigenesis by up-regulating PKM2 expression. Exp Cell Res 2021;408:112872. [PMID: 34648844 DOI: 10.1016/j.yexcr.2021.112872] [Reference Citation Analysis]
24 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
25 Du X, Li H, Yang X, Li J, Xu J, Chen Y, Xu Q, Yang L, He C, Huang C, Meng X, Li J. Wogonin attenuates liver fibrosis via regulating hepatic stellate cell activation and apoptosis. International Immunopharmacology 2019;75:105671. [DOI: 10.1016/j.intimp.2019.05.056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
26 Luo X, Sui J, Yang W, Sun Q, Ma Y, Simon TG, Liang G, Meyerhardt JA, Chan AT, Giovannucci EL, Zhang X. Type 2 Diabetes Prevention Diet and Hepatocellular Carcinoma Risk in US Men and Women. Am J Gastroenterol 2019;114:1870-7. [PMID: 31688024 DOI: 10.14309/ajg.0000000000000450] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
27 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]
28 Yoo JH, Kang M, Kim G, Hur KY, Kim JH, Sinn DH, Jin SM. Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease. J Diabetes Investig 2021;12:1252-62. [PMID: 33135331 DOI: 10.1111/jdi.13455] [Reference Citation Analysis]
29 Li W, Deng R, Liu S, Wang K, Sun J. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors. Liver Int 2020;40:2316-25. [PMID: 32666675 DOI: 10.1111/liv.14607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, Pan B, Guo W, Li X, Gao X. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26:444-453. [PMID: 31968197 DOI: 10.4158/ep-2019-0342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
31 Tomah S, Hamdy O, Abuelmagd MM, Hassan AH, Alkhouri N, Al-Badri MR, Gardner H, Eldib AH, Eid EA. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. BMJ Open Gastroenterol 2021;8:e000780. [PMID: 34610926 DOI: 10.1136/bmjgast-2021-000780] [Reference Citation Analysis]
32 Li F, Ye J, Sun Y, Lin Y, Wu T, Shao C, Ma Q, Liao X, Feng S, Zhong B. Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients. Diabetes Metab J 2021;45:417-29. [PMID: 33705650 DOI: 10.4093/dmj.2020.0039] [Reference Citation Analysis]
33 Yki-Järvinen H, Luukkonen PK. Diabetes, Liver Cancer, and Cirrhosis: What Next? Hepatology 2018;68:1220-2. [PMID: 30070729 DOI: 10.1002/hep.30136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Hong SH, Lee JS, Kim JA, Lee YB, Roh E, Hee Yu J, Kim NH, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi KM. Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study. Diabetes Res Clin Pract 2021;177:108922. [PMID: 34146602 DOI: 10.1016/j.diabres.2021.108922] [Reference Citation Analysis]
35 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Li Q, Xu H, Sui C, Zhang H. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol 2021;:101781. [PMID: 34332136 DOI: 10.1016/j.clinre.2021.101781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Cai S, Wu L, Yuan S, Liu G, Wang Y, Fang L, Xu D. Carvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway. Eur J Pharmacol 2021;898:173982. [PMID: 33647257 DOI: 10.1016/j.ejphar.2021.173982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Fan R, Niu J, Ma H, Xie Q, Cheng J, Rao H, Dou X, Xie J, Zhao W, Peng J, Gao Z, Gao H, Chen X, Chen J, Li Q, Tang H, Zhang Z, Ren H, Cheng M, Liang X, Zhu C, Wei L, Jia J, Sun J, Hou J; Chronic Hepatitis B Study Consortium. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Aliment Pharmacol Ther 2021;54:329-38. [PMID: 34157146 DOI: 10.1111/apt.16469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Falahi S, Rafiee-Pour HA, Zarejousheghani M, Rahimi P, Joseph Y. Non-Coding RNA-Based Biosensors for Early Detection of Liver Cancer. Biomedicines 2021;9:964. [PMID: 34440168 DOI: 10.3390/biomedicines9080964] [Reference Citation Analysis]
40 Liu D, Zhou L, Zhang X, Zeng Y, Bai L, Wu D, Tang H. Significantly Decreased Islet β Cell Function is Closely Associated with Hyperglycemia in Chronic Hepatitis B Patients. Int J Endocrinol 2021;2021:1264707. [PMID: 34497643 DOI: 10.1155/2021/1264707] [Reference Citation Analysis]
41 Chen J, Zhu J, Wang G, Groopman JD, Kensler TW. Qidong: a crucible for studies on liver cancer etiology and prevention. Cancer Biol Med 2019;16:24-37. [PMID: 31119044 DOI: 10.20892/j.issn.2095-3941.2018.0394] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
42 Liu X, Xu H, Zhan M, Niu J. The Potential Effects of Diabetes Mellitus on Liver Fibrosis in Patients with Primary Biliary Cholangitis. Med Sci Monit 2019;25:6174-80. [PMID: 31420961 DOI: 10.12659/MSM.916107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bockmann JH, Kohsar M, Murray JM, Hamed V, Dandri M, Lüth S, Lohse AW, Schulze-Zur-Wiesch J. High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. Microorganisms 2021;9:968. [PMID: 33946154 DOI: 10.3390/microorganisms9050968] [Reference Citation Analysis]
44 Li JJ, Jiang HC, Wang A, Bu FT, Jia PC, Zhu S, Zhu L, Huang C, Li J. Hesperetin derivative-16 attenuates CCl4-induced inflammation and liver fibrosis by activating AMPK/SIRT3 pathway. Eur J Pharmacol 2022;915:174530. [PMID: 34902361 DOI: 10.1016/j.ejphar.2021.174530] [Reference Citation Analysis]
45 Al-Muzafar HM, Amin KA. Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin. Exp Ther Med 2018;16:2938-48. [PMID: 30214514 DOI: 10.3892/etm.2018.6563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Soltani N, Marandi SM, Kazemi M, Esmaeil N. Meta-inflammatory state and insulin resistance can improve after 10 weeks of combined all-extremity high-intensity interval training in sedentary overweight/obese females: a quasi-experimental study. J Diabetes Metab Disord 2020;19:717-26. [PMID: 33520798 DOI: 10.1007/s40200-020-00550-z] [Reference Citation Analysis]
47 Zhao B, Hu T. JTC-801 inhibits the proliferation and metastasis of the Hep G2 hepatoblastoma cell line by regulating the phosphatidylinositol 3-kinase/protein kinase B signalling pathway. Oncol Lett 2019;17:1939-45. [PMID: 30675258 DOI: 10.3892/ol.2018.9780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Chen L, Abou-Alfa GK, Zheng B, Liu JF, Bai J, Du LT, Qian YS, Fan R, Liu XL, Wu L, Hou JL, Wang HY; PreCar Team. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res 2021;31:589-92. [PMID: 33589745 DOI: 10.1038/s41422-020-00457-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Zhang H, Li H, Lan X, Liu F, Li B, Wei Y. Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis. Medicine (Baltimore) 2021;100:e24354. [PMID: 33530229 DOI: 10.1097/MD.0000000000024354] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Grecian SM, McLachlan S, Fallowfield JA, Kearns PKA, Hayes PC, Guha NI, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF, Strachan MWJ. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.Liver Int. 2020;40:2252-2262. [PMID: 32638496 DOI: 10.1111/liv.14590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
51 Wu W, Jin G, Wang C, Miao Y, Wang H, Lou W, Yu X, Sun B, Li H, Qin R, Wu Z, Wang W, Xu K, Wang L, Liang T, Hao C, Huang H, Li Y, Tan G, Zhao Y, Hao J, Wang Y, Peng C, Liu X, Ou J, Yuan C, Wang X, Yang Y, Cai S, Guo K, Jiang J, Yu X, Wei J, Li F, Wu X, Zhao Y. The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. Journal of Pancreatology 2019;2:16-21. [DOI: 10.1097/jp9.0000000000000012] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
52 Cao M, Ding C, Xia C, Li H, Sun D, He S, Chen W. Attributable deaths of liver cancer in China. Chin J Cancer Res 2021;33:480-9. [PMID: 34584373 DOI: 10.21147/j.issn.1000-9604.2021.04.05] [Reference Citation Analysis]
53 Wang B, Li M, Zhao Z, Wang S, Lu J, Chen Y, Xu M, Wang W, Ning G, Bi Y, Wang T, Xu Y. Glycemic Measures and Development and Resolution of Nonalcoholic Fatty Liver Disease in Nondiabetic Individuals. J Clin Endocrinol Metab 2020;105:dgaa112. [PMID: 32144419 DOI: 10.1210/clinem/dgaa112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
54 Conway RBN, Sudenga S, McClain D, Blot WJ. Diabetes and liver cancer risk: A stronger effect in Whites than Blacks? J Diabetes Complications 2021;35:107816. [PMID: 33323327 DOI: 10.1016/j.jdiacomp.2020.107816] [Reference Citation Analysis]
55 Ramai D, Facciorusso A, Vigandt E, Schaf B, Saadedeen W, Chauhan A, di Nunzio S, Shah A, Giacomelli L, Sacco R. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells 2021;10:3401. [PMID: 34943908 DOI: 10.3390/cells10123401] [Reference Citation Analysis]
56 Pang Y, Lv J, Kartsonaki C, Yu C, Guo Y, Du H, Bennett D, Bian Z, Chen Y, Yang L, Turnbull I, Wang H, Li H, Holmes MV, Chen J, Chen Z, Li L. Association of physical activity with risk of hepatobiliary diseases in China: a prospective cohort study of 0.5 million people. Br J Sports Med 2021;55:1024-33. [PMID: 32826226 DOI: 10.1136/bjsports-2020-102174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Ge XJ, Du YX, Zheng LM, Wang M, Jiang JY. Mortality trends of liver cancer among patients with type 2 diabetes at the global and national level. J Diabetes Complications 2020;34:107612. [PMID: 32402842 DOI: 10.1016/j.jdiacomp.2020.107612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134:8-19. [PMID: 33323806 DOI: 10.1097/cm9.0000000000001263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
59 Huang S, Wang S, Xie Y, He X, Yi X, Zhang J, Deng Z, Yin L. Application of NRS2002 in Preoperative Nutritional Screening for Patients with Liver Cancer. J Oncol 2021;2021:8943353. [PMID: 34518766 DOI: 10.1155/2021/8943353] [Reference Citation Analysis]
60 Yang C, Lu Y, Xia H, Liu H, Pan D, Yang X, Sun G. Excess Body Weight and the Risk of Liver Cancer: Systematic Review and a Meta-Analysis of Cohort Studies. Nutr Cancer 2020;72:1085-97. [PMID: 31544511 DOI: 10.1080/01635581.2019.1664602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Bauvin P, Delacôte C, Lassailly G, Ntandja Wandji LC, Gnemmi V, Dautrecque F, Louvet A, Caiazzo R, Raverdy V, Leteurtre E, Pattou F, Deuffic-Burban S, Mathurin P. A tool to predict progression of non-alcoholic fatty liver disease in severely obese patients. Liver Int 2021;41:91-100. [PMID: 32881244 DOI: 10.1111/liv.14650] [Reference Citation Analysis]